Sun Pharma’s Semaglutide Injection Approved: A Strategic Analysis

Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to produce and sell a cheaper version of semaglutide injection. This injection helps adults manage their weight when used with a healthy diet and exercise. The approval opens the door for Sun Pharma to release ‘Noveltreat’ after the original semaglutide patent runs out in India.

Key Points

• Sun Pharma’s ‘Noveltreat’ approved for weight management in India.
• Injection available in five strengths, administered via prefilled pen.
• Addresses growing obesity and diabetes concerns within India.
• Meets global quality standards backed by Indian clinical trial data.
• Supports lifestyle changes alongside medication for best outcomes.
• Strategic move leveraging patent expiry and unmet patient needs.

Understanding Semaglutide

Semaglutide is a special medicine that works by mimicking a natural substance in your body called glucagon-like peptide-1 (GLP-1). It helps control your weight and can also improve how your body handles blood sugar. Doctors often use it for people who are overweight or have diabetes, particularly when combined with lifestyle changes.

Noveltreat Details

The new injection, called Noveltreat, comes in different strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Patients will use a simple pen to inject the medicine once a week. This convenient design makes it easier to stick to the treatment plan.

Strategic Launch

Sun Pharma plans to release Noveltreat after the original semaglutide patent expires in India. This means more people will have access to this medicine. The company is focused on tackling the increasing problems of obesity and type 2 diabetes in India. They’re using strong evidence from clinical trials to prove the medicine’s effectiveness.

Expert Perspectives

“We are committed to improving access to generic semaglutide across the country,” said Kirti Ganorkar, Managing Director of Sun Pharma. Doctors like Dr. Unnikrishnan A G emphasize the importance of combining semaglutide with a healthy diet and regular exercise for optimal results.

Additional Approval

Sun Pharma also received DCGI approval in December 2025 for semaglutide injection to treat adults with poorly controlled type 2 diabetes. The product will be launched under the brand name Sematrinity.

This approval represents a significant step in making effective weight management solutions more accessible to Indian patients.